EVALUATION OF SERUM INTERLEUKIN 15 IN PSORIATIC PATIENTS | ||
| ALEXMED ePosters | ||
| Article 1, Volume 5, Issue 3, September 2023, Pages 55-56 | ||
| Document Type: Preliminary preprint short reports of original research | ||
| DOI: 10.21608/alexpo.2023.237035.1695 | ||
| Authors | ||
| Nagat Sobhy Mohamed Eid1; Ahmed AbdElBary AbdElatief1; Hana Ali Donia2; Aya Ossama Farouk Salem* 1 | ||
| 1Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Alexandria University | ||
| 2Clinical Pathology Department, Faculty of Medicine; Alexandria University, Egypt. | ||
| Abstract | ||
| Psoriasis is a chronic skin condition with a wide range of clinical manifestations, including plaque, flexural, guttate, pustular, and erythrodermic lesions. It is an immune-mediated inflammatory condition with a strong hereditary component. It may be triggered by skin damage, infection, stress, and certain medication. Psoriasis is distinguished by epidermal proliferation and immune cell infiltration of the dermis. Psoriasis etiology is multifaceted, including the interaction of keratinocytes, immune cells, and other skin-resident cells. Activation of plasmacytoid dendritic cells (pDCs) increases the maturation and synthesis of TNF-, IL-12, and IL-23 by myeloid dendritic cells (mDCs), which leads to the activation of Th (T helper) 1 and Th17 and subsequent secretion of inflammatory cytokines such as TNF-, IL-17, IL-21, and IL-22. These cytokines subsequently activate keratinocytes, which generate antimicrobial peptides, cytokines, and chemokines, leading to the amplification of inflammation. IL-15 is a cytokine that plays a role in innate and adaptive immunity. In addition, it acts as a growth factor and promotes the survival of T, B, and NK cells by preventing apoptosis. | ||
| Keywords | ||
| INTERLEUKIN 15; PSORIATIC; EVALUATION | ||
|
Supplementary Files
|
||
|
Statistics Article View: 133 |
||
